Published in EBioMedicine on August 30, 2017
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A (1996) 4.49
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med (2008) 3.48
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer (2006) 2.70
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol (2005) 2.21
Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol (2005) 1.84
IL-2: the first effective immunotherapy for human cancer. J Immunol (2014) 1.71
Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res (2014) 1.48
Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat (2012) 1.39
Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett (2013) 1.24
Long-term survival with metastatic cancer to the brain. Med Oncol (2000) 1.21
Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep (2013) 1.19
Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol (1999) 1.16
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer (2009) 1.13
Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study. J Immunother (2011) 1.04
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget (2015) 0.97
Brain metastasis from ovarian cancer: a systematic review. J Neurooncol (2014) 0.92
Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer (2013) 0.87
Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS One (2014) 0.86
CAR T Cell Therapy for Solid Tumors. Annu Rev Med (2016) 0.85
Role of the systemic immune system in brain metastasis. Mol Cell Neurosci (2012) 0.83
Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report. Cancer (1991) 0.82
Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol (2016) 0.80
Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. Front Oncol (2016) 0.78
IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells. Oncoimmunology (2016) 0.78
Harnessing the IL-7/IL-7Rα axis to improve tumor immunotherapy. Oncoimmunology (2016) 0.78
Low-dose IL-2 therapy reduces HCV RNA and HBV DNA: case report. Anticancer Res (2009) 0.77
The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis. Arch Med Sci (2015) 0.76
Tumor-infiltrating lymphocytes (TILs) from patients with glioma. Oncoimmunology (2016) 0.75